Navigation Links
Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
Date:4/14/2008

Poster Presented at the 2008 AACR Annual Meeting

SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego.

In the poster titled "The inhibition of radiation repair by ranpirnase +/- I-buthionine sulfoximide on lung cancer," Dr. Lee provided pre-clinical evidence that ONCONASE +/- I-buthionine sulfoximide significantly increased the radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ONCONASE significantly increased apoptosis (programmed cell death) in several human non-small cell lung cancer (NSCLC) cell lines (A549, NCI-H1975 and HOP-62). Dr. Lee and his team of researchers also showed that the radiation repair mechanisms known as sub-lethal damage repair (SLDR) and potentially lethal damage repair (PLDR), which lead to radiation resistance in tumors, were significantly inhibited by ONCONASE in vitro.

"Our research suggests potential utility of ONCONASE as a radiotherapy enhancer for the treatment of NSCLC patients," said Dr. Lee. "It is important to overcome PLDR as it can ultimately lead to radiation resistance. One of our key findings is the inhibiting impact of ONCONASE on the PLDR mechanism, which is a pre-requisite to developing a radiotherapy enhancer."

Kuslima Shog
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... , STAMFORD, Conn., Nov. 13 ... it will be releasing a free trial version of its ... Sessions conference, taking place this November 15-17 in Orlando. Zargis ... of the companion hardware -- the 3M Littmann Electronic Stethoscope ...
... , , SILVER SPRING, Md., ... today approved Lysteda tablets (tranexamic acid), the first non-hormonal ... works by stabilizing a protein that helps blood to ... ) , Heavy menstrual bleeding is reported each year ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... make citizens pay for others, abortions , Senate ... Bill doesn,t meet goals of affordability, fairness to legal ... Responding to reports of a new "compromise" proposal on abortion ... DiNardo today reaffirmed the position of the U.S. Conference of ...
... predestine anyone to abuse either, researchers say, , FRIDAY, Dec. ... to alcoholism also make them prone to becoming addicted to ... men and women aged 24 to 36, including almost 2,800 ... Registry, about their use of alcohol and marijuana over their ...
... ... consequences, won two prestigious honors: a place on The Washington Post’s Best Books of ... the coveted award. , ... Washington, DC (PRWEB) December 18, 2009 -- Steve Luxenberg’s Annie’s Ghosts: A Journey ...
... Dec. 18 Nationwide Health Properties, Inc. (NYSE: ... it is redeeming all of its outstanding shares of 7.75% ... (NHP-PB - CUSIP No. 638620302) on January 18, 2010 at ... equal to accumulated and unpaid dividends thereon to the redemption ...
... fruit rind fights drug-resistant infections, researchers say , ... can be turned into an ointment to treat ... dangerous methicillin-resistant Staphylococcus aureus (MRSA) bacteria, ... experiments, the team at Kingston University in London ...
... Dec. 18 Feeding America, the nation,s leading domestic hunger-relief ... more than $400,000 in adult and pediatric nutritionals originally intended ... 20 food banks in seven states and Puerto Rico. ... on a partnership to "pre-position" nutritional products to regions that ...
Cached Medicine News:Health News:'Abortion Compromise' Does Not Address Core Problem In Senate Health Bill, Says Cardinal DiNardo, Bishops' Pro-Life Chair 2Health News:'Abortion Compromise' Does Not Address Core Problem In Senate Health Bill, Says Cardinal DiNardo, Bishops' Pro-Life Chair 3Health News:Marijuana, Alcohol Addiction May Share Genes 2Health News:Marijuana, Alcohol Addiction May Share Genes 3Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 2Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 3Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:More Medicinal Uses for Pomegranate 2Health News:Feeding America and Abbott Transform Disaster Preparedness Into Hunger Relief 2Health News:Feeding America and Abbott Transform Disaster Preparedness Into Hunger Relief 3
... The EBV laboratory diagnosis is generally confirmed ... Severity of the disease however, is not indicated ... IM occurs in 10 - 20 percent of ... EBV are necessary to fully ascertain the stage ...
... IDI-Strep B test can lower healthcare costs ... hospital stays. By identifying mothers colonized with ... more targeted and effective antibiotic prophylaxis. This ... of infants and reduce unnecessary antibiotic use ...
... Needle is specially designed to help you ... reliable core sample. All needles are engineered ... polished surfaces for smooth entry and exit. ... needle sizes assures an ideal match with ...
... Used to obtain multiple core biopsies of ... Biopsy Needle design facilitates one-handed control. Precise, ... sample. Beveled point stylet permits easy penetration ... surrounding tissue. Sharp cutting edge of cannula ...
Medicine Products: